Goodwin represented PAI Partners and the management of Cerba in the sale of Cerba HealthCare, a European leader in the clinical pathology business, to a consortium led by Partners Group and Public Sector Pension Investment Board. Goodwin also advised on the structure and implementation of the investment of a large number of managers of the group in the new transaction. The terms of the transaction were not disclosed.
PAI Partners is a leading European private equity firm with offices in Paris, London, Luxembourg, Madrid, Milan, Munich, New York and Stockholm. PAI manages €8.3 billion of dedicated buyout funds. Since 1994, the company has completed 61 transactions in 11 countries, representing c. €41 billion in transaction value.
Cerba HealthCare is an international group of medical biology (mainly active in France, Belgium, Luxembourg and the Middle East), which generated revenues of approximately €630 million in 2016.
The Goodwin team was led by partners Maxence Bloch, William Robert, Marie-Laure Bruneel and Frédéric Guilloux and Thomas Dupont-Sentilles.
Cerba HealthCare is a longstanding client of Goodwin and is advised regularly on various matters including corporate, acquisitions, tax structuring, regulatory and litigation. The firm advised Cerba HealthCare on its acquisition of MenaLabs in 2016.
For additional details on the transaction, please read the press release.